Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck

European Journal of Cancer. Part B: Oral Oncology

Volumn 28, Issue 1, 1992, Pages 67-76

  Field, J K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, VIRAL; CHROMOSOMES, HUMAN, PAIR 11; DNA TUMOR VIRUSES; GENE AMPLIFICATION; GENES, MYC; GENES, P53; GENES, RAS; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMAN; PAPILLOMAVIRUS; PROTO-ONCOGENES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0026636412     PISSN: 09641955     EISSN: None     Source Type: Journal    
DOI: 10.1016/0964-1955(92)90016-T     Document Type: Article

References (130)

1. The molecular genetics of cancer
2. The biology of oncogenes and their role in malignant transformation
3. Evolution of tumours and their impact on molecular oncology
4. Hereditary cancer, oncogenes and anti-oncogenes
5. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product
6. Association of human Papillomavirus types 16 and 18 E6 proteins with p53
7. myc oncogenes: activation and amplification
8. Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas
9. The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis. A review
10. ras genes
11. ras Oncogenes in human cancer: A review
12. Prevalence of ras gene mutations in human colorectal cancers
13. Detection of high incidence of Ki-ras oncogenes during human colon tumorigenesis
14. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas
15. Carcinogenspecific mutation and amplification of Ha-ras during mouse skin carcinogenesis
16. Differential expression of cellular oncogenes in benign and malignant human breast tissue
17. Immunohistochemical study of the ras oncogene expression in human breast lesions
18. Expression of the 21,000 molecular Wt ras protein in a spectrum of benign and malignant human mammary tissues
19. Immunocytochemical demonstration and significance of ras p21 family oncogene product in benign and malignant breast disease
20. Amplified expression of ras p21 protein in hormone-dependent mammary carcinomas of humans and rodents
21. The H-ras oncogene product p21 and prognosis in human breast cancer
22. Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 in human breast cancer
23. Elevated ras oncogene expression correlates with lymph node metastasis in breast cancer patients
24. Expression of p21 ras gene products in breast cancer relates to histological types and to receptor and nodal status
25. A genetic model for colorectal tumorigenesis
26. Genetics alterations during colorectal-tumor development
27. Expression of Ha-ras oncogene in human neuroblastomas and the significant correlation with patient prognosis
28. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent
29. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India
30. Low incidence of ras oncogene activation in human squamous cell carcinomas
31. Ras mutations in United Kingdom examples of oral malignancies are infrequent
32. Low incidence of point mutation at codon 12 of K-ras proto-oncogene in squamous cell carcinoma of the upper aerodigestive tract
33. Clinical relevance of oncogene expression in head and neck tumours
34. Amplification of the int-2 gene in human and neck squamous cell carcinomas
35. Oncogene amplification in squamous cell carcinoma of the head and neck
36. Analysis of gene amplification in head and neck squamous cell carcinomas
37. Oncogene amplification in squamous cell carcinoma of the oral cavity
38. Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumours
39. The relation of ras oncogene product p21 expression to clinico pathological status and clinical outcome in squamous cell head and neck cancer
40. The immunohistochemical detection of ras p21 and its correlation with differentiation in oral cancers
41. Loss of allelic heterozygosity at the harvey ras locus in human oral carcinomas
42. Mortality in relation to smoking: 20 years observations on male doctors
43. Comparative epidemiology of tobacco related cancers
44. Prognostic implications of ras oncogene expression in head and neck squamous cell carcinoma
45. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma
46. Expression of c-erbB-2 and c-myc in squamous epithelia and squamous cell carcinomas of the head and neck and the lower female genital tract
47. Immunohistochemical localization of c-myc oncogene product and EGF receptor in oral squamous cell carcinoma
48. Immunohistochemical study of c-myc expression in head and neck cancer: A prognostic indicator
49. Alterations to either c-erb B-2 (neu) or c-myc protooncogenes in breast carcinomas correlate with poor short-term prognosis
50. Proto-oncogenes and prognosis in early carcinoma of the uterine cervix
51. Frequent rearrangement of chromosome bands 1p22 and 11q13 in squamous cell carcinomas of the head and neck
52. Chromosome 11q13 abnormalities in human cancer
53. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma
54. Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumours
55. bcl-1, t(11; 14) and mantle cell-derived lymphomas
56. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11; 14) chromosome translocation
57. Coamplification of the hst-1 and int-2 genes in human cancers
58. Frequent amplification of the bcl-1 locus in head and neck squamous cell carcinomas
59. Amplification of int-2 in breast cancers and squamous carcinomas
60. The structure and function of the int-2 oncogene
61. Genomic sequence of hst, a transforming gene encoding a protein homologous to fibroblast growth factors and the int-2-encoded protein
62. A novel cyclin encoded by a bcl1-linked candidate oncogene
63. Cyclins: wheels within wheels
64. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1
65. The erbB gene of avian erythroblastosis virus is a member of the src gene family
66. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas
67. Analysis of the epidermal growth factor receptor gene in fresh human head and neck tumours
68. Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck
69. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
70. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor recetor
71. c-erbB-2 oncogene as a prognostic marker in breast cancer
72. Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer
73. Immunohistochemical localization of c-erbB-2 in human breast carcinomas
74. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer prognostic significance
75. The c-erbB-2 Proto-oncogene in human pancreatic cancer
76. The Neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients
77. Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck
78. Expression of p53 in premalignant and malignant squamous epithelium
79. E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis
80. Dominant and recessive genes involved in tumour cell invasion
81. T antigen is bound to a host protein in SV40-transformed cells
82. The p53 tumour suppressor gene
83. The p53 proto-oncogene can act as a suppressor of transformation
84. Mutation is required to activate the p53 gene for co-operation with the ras oncogene and trans-formation
85. p53 mutations in human cancers
86. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies
87. p53 Gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis
88. p53 expression in colorectal tumors
89. Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro
90. The cellular protein p53 in human tumours
91. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas
92. P53 Expression human breast cancer related to survival and prognostic factors: an immunohistochemical study
93. p53: oncogene or anti-oncogene?
94. Increased expression of mutant forms of p53 oncogene in primary lung cancer
95. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer
96. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma
97. Overexpression of the p53 gene in head and neck cancer, linked with heavy smoking and drinking
98. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer
99. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
100. Papillomaviruses: The current status in relation to oral disease
101. Epithelial cell adhesion molecules
102. Molecular nature of the calcium-dependent cell-cell adhesion system in mouse teratocarcinoma and embryonic cells studied with a monoclonal antibody
103. Dissecting tumor cell invasion: Epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion
104. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells
105. Unstable expression of E-cadhesion molecules in metastatic ovarian tumor cells
106. Cadherin intercellular adhesion molecule in hepatocellular carcinomas: Loss of E-cadherin expression in an undifferentiated carcinoma
107. Regional assignment of the human loci for uvomorulin (UVO) and chymotrypsinogen B (CTRB) with the help of two overlapping deletions on the long arm of chromosome 16
108. Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma
109. Allelotype of breast cancer: cumulative allele losses promote tumour progression in primary breast cancer
110. Allelic loss of chromosomes 16q and 10q in human prostate cancer
111. Detection of human papillamavirus in formalin-fixed invasive squamous carcinomas using the polymerase chain reaction
112. Nasophomngeal carcinoma
113. The Epstein-Barr virus in neoplasms of the head and neck
114. Evidence for infection agents in the aetiology of oral cancer
115. Papillomavirus in human cancers
116. Detection of human papillomavirus DNA in biopsies of human oral tissue
117. High prevalence of human papillomavirus infection and possible association with betel quid chewing and smoking in oral epidermoid carcinomas in Taiwan
118. Human papilloma virus in erosive oral lichen planus
119. Human papillomavirus DNA biopsies of oral tissues
120. Integration of papillomavirus DNA near myc genes in gential carcinomas and its consequences for proto-oncogene expression
121. Status of c-myc p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus
122. High correlation between molecular alterations of the c-myc oncogene and carcinoma of the uterine cervix
123. C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix
124. Alterations of myc, myb and rasHa proto-oncogene in cancers are frequent and show clinical correlations